Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin (R)) in patients with relapsed or refractory mantle cell lymphoma (MCL) After/not appropriate for autologous stem CA transplantation (ASCT) - A phase II trial of the